Protein phosphorylation has been the target of many drugs, both approved and under development, as well as diagnostics. Phosphorylation status lies beyond the capability of transcriptomics or genomics and is commonly addressed with antibody-based techniques. Most commercially available phospho-antibodies show a moderate-to-high lack of both specificity and sensitivity in immunostainings. It results in generating false-positive or false-negative results and inaccurate data. This is particularly problematic in fields that use antibodies to analyze proteins that are modified at low levels.
Applying pan antibodies against protein modifications together with protein-specific antibodies in NaveniFlex dual-recognition assays guarantees the highest specificity of PTM detection. Consequently, it decreases the need for new antibody production and validation.